In early October, the Food and Drug Administration (FDA) approved a combination ledipasvir-sofosbuvir pill (Harvoni) to treat chronic hepatitis C virus infection. The pill is the first combination pill approved to treat chronic HCV genotype 1 infection and the first approved regimen that does not require administration with interferon or ribavirin.|
IDSA offers two email services to help members stay informed of new drug approvals and similar updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)
Is Your Facility Experiencing Antibiotic Shortages?IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at email@example.com.
< Previous Article | Next Article >